We hypothesize that the first phase of BC carcinogenesis is characterized by high levels of Mfn2, which however tends to decrease by increasing disease stage and grade, thus making Mfn2 down-regulation a marker of aggressiveness and predisposition to progress in patients with NMIBC. This evidence concerns the gene MFN2 and breast cancer.